STOCK TITAN

AIM ImmunoTech Inc. - AIM STOCK NEWS

Welcome to our dedicated page for AIM ImmunoTech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech stock.

AIM ImmunoTech Inc. (NYSE American: AIM) is a pioneering immuno-pharma company based in Ocala, Florida, focused on the research and development of innovative therapeutics aimed at treating a variety of cancers, immune disorders, and viral diseases including COVID-19. The company's flagship product is Ampligen® (rintatolimod), a first-in-class investigational drug that acts as a highly selective TLR3 agonist immuno-modulator with broad-spectrum activity. Ampligen is currently undergoing extensive clinical trials targeting globally important cancers and viral diseases.

AIM ImmunoTech's product portfolio also includes Alferon N Injection, an injectable formulation of natural alpha interferon used to treat a specific category of genital warts, a sexually transmitted disease. Ampligen has shown promising results in the treatment of chronic fatigue syndrome and is being developed for other indications like hepatitis B, HIV, and several cancer types, including renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, urothelial cancer, prostate cancer, and pancreatic cancer.

In recent developments, AIM ImmunoTech announced positive top-line interim data indicating that the combination of Ampligen with Keytruda (pembrolizumab) could be significantly more effective than pembrolizumab alone in treating recurrent ovarian cancer. The company is also working on various clinical trials, including studies for treating post-COVID conditions and long COVID, led by renowned medical experts like Dr. Charles Lapp.

AIM ImmunoTech has formed strategic research agreements with prominent institutions such as the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., exploring the potential of Ampligen as an adjuvant therapy for COVID-19. The company continues to focus on operational execution and has successfully completed cGMP manufacturing of over 9,000 clinical vials of Ampligen, which is crucial for its ongoing and upcoming clinical trials.

The company's leadership team, headed by CEO Thomas K. Equels, is committed to advancing its pipeline and achieving clinical and commercial success. AIM ImmunoTech engages with its stakeholders through regular updates and CEO Corner segments, providing insights into its clinical programs and financial performance, ensuring transparency and fostering investor confidence.

For more detailed information, visit the official website and connect with AIM ImmunoTech on social media platforms such as X, LinkedIn, and Facebook.

Rhea-AI Summary

AIM ImmunoTech has received formal notification from the European Commission approving its Orphan Medicinal Product Application for Ampligen, aimed at treating pancreatic cancer. This designation grants AIM up to ten years of market exclusivity in the EU. Ampligen is expected to be a significant treatment option, with potential survival benefits demonstrated in trials. The company is currently pursuing further studies and FDA fast-track status to expedite its clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) has received Ethics Committee approval in the Netherlands for its Phase 1 clinical study of Ampligen as an intranasal therapy for COVID-19 and respiratory viral diseases. The study will enroll 40 healthy subjects to evaluate safety and tolerability over 13 days. CEO Thomas K. Equels expressed optimism about the potential of Ampligen, noting previous results that showed a 90% reduction in SARS-CoV-2 infection in vitro. Enrollment is expected to start in Q1 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
-
Rhea-AI Summary

AIM ImmunoTech has received approval from the Dutch Health and Youth Care Inspectorate for a new Early Access Program to treat pancreatic cancer patients with rintatolimod (Ampligen) at Erasmus Medical Center. The initiative follows the success of a prior program, which demonstrated a significant survival benefit. Up to 16 patients will be treated, and the program aims to enhance patient selection. AIM plans to advance to clinical trials in the EU and U.S., seeking Fast Track status to expedite approval. The orphan drug designation offers ten years of market protection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.05%
Tags
none
Rhea-AI Summary

AIM ImmunoTech Inc. (AIM) has completed its At-The-Market (ATM) facility and closed its Equity Distribution Agreement (EDA). The company asserts it has sufficient funds to support its operational needs and clinical trials for the next 24 months. AIM plans to independently finance key developmental programs in oncology, COVID-19, ME/CFS, and Long COVID, aiming for significant advancements in 2021. CEO Thomas K. Equels highlighted the company's financial stability and commitment to achieving objectives without a renewed ATM facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.91%
Tags
-
Rhea-AI Summary

AIM ImmunoTech has partnered with the Centre for Human Drug Research to conduct a clinical study on its Ampligen drug as an intranasal therapy for COVID-19. The study, titled "A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen," will enroll 40 healthy subjects and is fully funded by AIM. Results may provide crucial insights into the potential of Ampligen as a COVID-19 treatment, though future success is uncertain and dependent on many factors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech has rescheduled its investor conference call for January 21, 2021, at 11:00 a.m. ET. The call will focus on the amended AMP-511 trial treating patients with COVID-19-induced chronic fatigue symptoms, recent achievements, and future milestones. Interested parties can submit questions to management before the call. The conference will be accessible on AIM ImmunoTech's website, and a replay will be available for 90 days post-call. AIM is committed to developing therapeutics targeting various cancers, immune disorders, and viral diseases, including COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) has announced the postponement of its upcoming investor conference call due to the recent passing of CEO Thomas K. Equels' mother. The company remains committed to its focus on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. The new date for the investor call will be communicated later.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech has initiated the dosing of its first COVID-19 'Long Hauler' patient in the AMP-511 Expanded Access Program (EAP) with Ampligen (rintatolimod). This program addresses chronic post-COVID-19 symptoms. AIM plans to host a conference call on January 12, 2021, to update on this trial and their ongoing advancements. The EAP will enroll up to 100 participants suffering from Chronic Fatigue Syndrome, including 20 Long Haulers. AIM's CEO emphasized the urgency of developing effective therapies for these long-term COVID effects, highlighting Ampligen’s potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
covid-19
-
Rhea-AI Summary

AIM ImmunoTech Inc. announced that the post-COVID-19 'Long Hauler' segment of its AMP-511 Expanded Access Program received Institutional Review Board approval for public notification of patient enrollment. The trial will include treatments with their drug Ampligen, targeting chronic fatigue symptoms in COVID-19 survivors identified as 'Long Haulers'. Up to 100 participants may be enrolled, with 20 allocated to Long Haulers. The program aims to address a significant public health need as millions face ongoing symptoms of fatigue post-COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
clinical trial covid-19
Rhea-AI Summary

AIM ImmunoTech has announced the approval of its post-COVID-19 Long Hauler clinical trial for its drug Ampligen. The Institutional Review Board (IRB) has authorized public notification for enrollment, allowing up to 100 participants, including 20 Long Haulers experiencing chronic fatigue post-COVID-19. Ampligen, an immune-system modulator, is already approved for Chronic Fatigue Syndrome in Argentina and is the only late-stage candidate in the U.S. for ME/CFS. AIM aims to address the critical health need for therapies targeting chronic fatigue resulting from COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
clinical trial covid-19

FAQ

What is the current stock price of AIM ImmunoTech (AIM)?

The current stock price of AIM ImmunoTech (AIM) is $0.2051 as of December 5, 2024.

What is the market cap of AIM ImmunoTech (AIM)?

The market cap of AIM ImmunoTech (AIM) is approximately 13.1M.

What is AIM ImmunoTech's main focus?

AIM ImmunoTech focuses on developing therapeutics to treat various cancers, immune disorders, and viral diseases, including COVID-19.

What are AIM ImmunoTech's key products?

The company's key products include Ampligen (rintatolimod), a TLR3 agonist immuno-modulator for cancer and viral diseases, and Alferon N Injection for treating genital warts.

What recent achievements has AIM ImmunoTech made?

Recent achievements include positive interim data for Ampligen combined with Keytruda in ovarian cancer treatment, and the successful manufacturing of over 9,000 clinical vials of Ampligen.

Who are AIM ImmunoTech's notable partners?

AIM ImmunoTech has research agreements with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. for developing Ampligen as a COVID-19 therapy.

What clinical trials is AIM ImmunoTech currently conducting?

The company is conducting clinical trials for various cancers, chronic fatigue syndrome, and COVID-19 related conditions.

How can investors access AIM ImmunoTech's financial reports?

Investors can access financial reports on AIM ImmunoTech's official website and the U.S. Securities and Exchange Commission (SEC) filings.

How does AIM ImmunoTech engage with its stakeholders?

AIM ImmunoTech engages stakeholders through regular updates, CEO Corner segments, and social media platforms like X, LinkedIn, and Facebook.

What is the significance of Ampligen in AIM ImmunoTech's portfolio?

Ampligen is a cornerstone of AIM ImmunoTech's portfolio, showing broad-spectrum activity in clinical trials for cancers, viral diseases, and immune disorders.

Who leads AIM ImmunoTech?

The company is led by CEO Thomas K. Equels, who focuses on advancing the company's pipeline and achieving clinical and commercial success.

Where can more information about AIM ImmunoTech be found?

More information can be found on the company's official website, aimimmuno.com, and its social media channels.

AIM ImmunoTech Inc.

NYSE:AIM

AIM Rankings

AIM Stock Data

13.13M
57.95M
8.57%
14.08%
0.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
OCALA